Karen Sundell has over 30 years of experience in drug development, spanning discovery research through Phase 4 clinical trial design, implementation, analysis and data dissemination. Karen was at Eli Lilly and Company for 29 years, with her last 10 years as Principal Research Scientist on the Alzheimer’s Disease Platform Team, responsible for Phase 3 clinical development. Karen has co-authored over 40 peer-reviewed journal publications and has a broad range of experience that includes cross-functional data collection, validation, interpretation and visualization; dataflow and processing; clinical trial design and implementation; technical, medical and strategic leadership including risk mitigation and contingency planning. Karen joined Acumen in 2020.